CompBrief BY VELARION

Companies Inari Medical, Inc.

Inari Medical CEO salary & total pay, FY2023: $5.1M

Inari Medical (INRI) CEO salary, fiscal 2023: Andrew Hykes was paid a salary of $700,000 and $5,083,365 in total compensation. Free brief. Every figure links to the company’s own filing.

Inari Medical, Inc. no longer files a proxy statement; its last pay data is FY2023.

All products and prices

Andrew Hykes's complete compensation dossier

A PDF and a CSV sent to your email: Andrew Hykes's pay in every fiscal year Inari Medical, Inc. reported it, line by line, with Andrew Hykes's equity grants and Inari Medical, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$5,083,365CEO Andrew Hykes · source
Say-on-pay support95.35%Latest vote · source
CEO vs. named peers7th pct.Of 17 peer CEOs

CEO pay, last three years

  • $5,083,365FY2023

CEO total pay was $5,083,365 in fiscal 2023; the brief holds no earlier figure for this CEO.

FY2023: salary $700,000 · bonus $0 · stock awards $2,606,744 · option awards $937,488

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Inari Medical, Inc. in fiscal 2023?
As disclosed, Andrew Hykes (Chief Executive Officer) was the highest-paid executive at Inari Medical, Inc. in fiscal 2023, with total compensation of $5,083,365.
How does Inari Medical, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Andrew Hykes's total compensation ranked at the 7th percentile of Inari Medical, Inc.'s disclosed peer group.
How did shareholders vote on Inari Medical, Inc.'s executive compensation?
As disclosed, 95.35% of shareholders supported Inari Medical, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Inari Medical, Inc. spend in total on board compensation for fiscal 2023?
As disclosed, Inari Medical, Inc. reported total board compensation of $2,039,770 for fiscal 2023.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Andrew Hykes$700,000$0$2,606,744$937,488$826,000$0$13,133$5,083,365
Chief Executive Officer
Thomas Tu497,50001,199,072431,242354,000014,1332,495,947
Chief Medical Officer
Mitchell Hill497,50001,199,072431,242354,000013,1332,494,947
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2023 totalFY2022 totalFY2021 totalΔ FY2022→2023
Andrew Hykes$5,083,365$3,127,714$2,563,026↑ +1,955,651
Thomas Tu2,495,9472,323,4921,960,794↑ +172,455
Mitchell Hill2,494,9472,321,6291,895,921↑ +173,318

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation programs are designed to align the interests of our executives with business priorities and stockholders, attract, retain, engage, and motivate talented executive officers, and remain market competitive and internally equitable.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantFW Cook
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingfalse
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2023

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Mitchell HillRSU2023-02-18——21,412—$1,199,072
Thomas TuRSU2023-02-18——21,412—1,199,072
Thomas TuOPTION2023-02-18——16,599—431,242
Andrew HykesOPTION2023-02-18——36,085—937,488
Andrew HykesRSU2023-02-18——46,549—2,606,744
Mitchell HillOPTION2023-02-18——16,599—431,242

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Mitchell Hill$1,199,072$0$431,2420.0%
Thomas Tu1,199,0720431,2420.0%
Andrew Hykes2,606,7440937,4880.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2023

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Andrew HykesRSU—4,008—$260,199
Andrew HykesRSU—14,940—969,905
Andrew HykesOption9,02127,06356—
Andrew HykesRSU—34,912—2,266,487
Andrew HykesOption161,100—0.43—
Andrew HykesOption16,719—0.46—
Andrew HykesOption16,719—6.45—
Mitchell HillRSU—2,673—173,531
Mitchell HillRSU—9,968—647,123
Mitchell HillOption4,14912,45056—
Mitchell HillRSU—16,059—1,042,550
Mitchell HillOption94,477—0.46—
Thomas TuRSU—2,673—173,531
Thomas TuRSU—9,968—647,123
Thomas TuOption—12,45056—
Thomas TuRSU—16,059—1,042,550
Thomas TuOption139,584—0.46—
Thomas TuOption4,149—6.45—
Thomas TuOption8,420—0—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Donald MilderIndependent · Board Chair · Compensation$105,500$160,968———$266,428
Cynthia LuccheseIndependent · Audit · Nominating/Governance · Risk75,000160,928———235,928
Jonathan Root, M.DIndependent · Compensation · Nominating/Governance70,000160,968———230,928
Kirk NielsenIndependent · Compensation · Nominating/Governance · Not standing for re-election66,134160,968———227,062
Rebecca ChambersIndependent · Audit · Nominating/Governance · Compensation60,000160,928———220,928
Robert WarnerIndependent · Audit · Nominating/Governance · Compensation60,000160,968———220,928
Catherine SzymanIndependent · Compensation59,544160,968———220,472
Dana G. Mead JrIndependent · Compensation57,500160,968———218,428
William HoffmanNot independent · Nominating/Governance37,500160,928———198,428
Andrew HykesEmployee director—————0

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$160,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2023
Cash retainers and fees$591,178
Equity awards (grant-date value)$1,448,592
All other compensation$0
Total cost of the board$2,039,770

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Inari Medical as a peer

Companies that benchmark against INRI

3 companies name INRI as a compensation peer

Each company listed discloses INRI in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named INRI in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2023

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Peer reciprocity

The companies Inari Medical, Inc. names as compensation peers that name it back in their own disclosed peer groups.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Silk Road Medical2023Chas McKhann$105,871$13,123,059$0$93,275$13,423,834
2NovoCure2025Ashley Cordova901,8378,249,9652,752,814811,65313,198,354
3Abiomed2022Michael Minogue788,6316,557,7243,072,5612,237,83612,665,992
4Glaukos2025Thomas Burns850,0007,649,9473,527,497012,034,087
5Nevro2023Kevin Thornal515,62510,080,1730402,75011,453,548
6iRhythm Technologies2025Quentin Blackford700,0038,919,45701,350,00011,003,163
7AtriCure2025Michael Carrel828,4397,203,47801,171,7039,217,620
8ShockWave Medical2022Doug Godshall644,2316,845,6600923,6508,418,871
9LivaNova2025Vladimir Makatsaria956,1154,303,0921,374,9991,287,6568,047,217
10Inspire Medical Systems2025Timothy Herbert750,5725,999,6550961,5577,711,784
11Staar Surgical Company2025Stephen Farrell580,0006,836,000007,522,385
12Artivion2025J. Patrick Mackin835,1455,006,9900991,3686,883,108
13Tandem Diabetes Care2025John Sheridan790,5835,367,7960674,0906,858,503
14AngioDynamics2026James Clemmer828,1713,689,86601,502,4916,060,145
15Inari Medical, Inc.2023Andrew Hykes700,0002,606,744937,488826,0005,083,365
16Penumbra2025Adam Elsesser850,000000851,621
—Cardiovascular Systems——————not in coverage universe

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Inari Medical, Inc.not disclosedRSU 75 · Option 25not disclosedFW Cook
Abiomednot disclosedPSU 50 · RSU 30 · Option 20not disclosedWillis Towers Watson
AngioDynamics180%PSU 50 · RSU 50NoMeridian Compensation Partners, LLC
Artivion118.7%PSU 50 · RSU 50NoWillis Towers Watson
AtriCurenot disclosedPSU 50 · Restricted Stock 50NoKorn Ferry
Cardiovascular Systemsnot disclosednot disclosednot disclosednot disclosed
Glaukosnot disclosedRSU 50 · PRSU 50NoFrederic W. Cook & Co., Inc.
Inspire Medical Systems111.4%PSU 50 · RSU 50NoAon
iRhythm Technologies173%RSU 50 · PSU 50Yes — Relative TSRAon and Mercer
LivaNova122.4%PSU 50 · RSU 25 · Options 25NoPearl Meyer
Nevro53.7%RSU 50 · PSU 50NoAon
NovoCure100%PSU 50 · RSU 25 · Options 25NoFrederic W. Cook & Co., Inc.
Penumbranot disclosednot disclosedNoCompensia
ShockWave Medical142.1%RSU 50 · PRSU 50NoCompensia
Silk Road Medical86.1%PSU 50 · RSU 50Yes — Total Stockholder Return (TSR) relative to peer groupCompensia, Inc.
Staar Surgical Company135%RSU 50 · PSU 50NoSemler Brossy
Tandem Diabetes Care87%PSU 50 · RSU 50Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027WTW

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20242024-04-2444,404,4872,164,720546,05895.35%Passed
20232023-05-1842,519,0093,417,294111,00392.56%Passed
20222022-05-2636,070,0165,283,156115,99787.22%Passed
20212021-05-27—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20242024-04-2495.35%a
20232023-05-1892.56%b
20222022-05-2687.22%c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be considered votes cast on Proposal No. 3 and will have no effect on this proposal.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be considered votes cast on Proposal No. 3, and thus will have no effect on this proposal.”.

c. Approved under the standard stated in the filing — “The approval by the holders of a majority in voting power of the votes cast affirmatively (excluding abstentions and broker non votes), or "Majority Cast," is required with regard to the ratification of the selection of our independent registered public accounting firm, approval on an advisory basis, of the compensation of our named executive officers, and the approval, on an advisory basis, on the frequency of future non-binding votes on the compensation our named executive officers.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Thomas TuChief Medical Officer2025-01-01D699$51$35,684CommonForm 4 ↗
William HoffmanDirector2025-01-01D1,5335178,260CommonForm 4 ↗
William HoffmanDirector2025-01-01D7135136,399CommonForm 4 ↗
Thomas TuChief Medical Officer2025-01-01D5165126,342CommonForm 4 ↗
Thomas TuChief Medical Officer2025-01-01D7515138,339CommonForm 4 ↗
Kevin T. StrangeChief Financial Officer2025-01-01D146517,453CommonForm 4 ↗
Thomas TuChief Medical Officer2025-01-01D3375117,204CommonForm 4 ↗
Kevin T. StrangeChief Financial Officer2025-01-01D2275111,588CommonForm 4 ↗
Kevin T. StrangeChief Financial Officer2025-01-01D176518,985CommonForm 4 ↗
Kevin T. StrangeChief Financial Officer2025-01-01D63513,216CommonForm 4 ↗
Andrew HykesDirector2025-01-01D1,3195167,335CommonForm 4 ↗
Andrew HykesDirector2025-01-01D5095125,984CommonForm 4 ↗
Kevin T. StrangeChief Financial Officer2025-01-01D2765114,090CommonForm 4 ↗
Andrew HykesDirector2025-01-01D9495148,446CommonForm 4 ↗
Andrew HykesDirector2025-01-01D1,6325183,314CommonForm 4 ↗
Kevin T. StrangeChief Financial Officer2025-01-01D149517,606CommonForm 4 ↗
William HoffmanDirector2025-01-06D58,925613,610,335CommonForm 4 ↗
William HoffmanDirector2025-01-06D141,075608,482,840CommonForm 4 ↗
Andrew HykesDirector2025-02-04A67,28200CommonForm 4 ↗
Thomas TuChief Medical Officer2025-02-04A21,10200CommonForm 4 ↗
Kevin T. StrangeChief Financial Officer2025-02-04A21,10200CommonForm 4 ↗
Karen SilvaPrincipal Accounting Officer2025-02-04A5,50400CommonForm 4 ↗
Thomas TuChief Medical Officer2025-02-10D8,42000Derivative, Class A CommonForm 4 ↗
Thomas TuChief Medical Officer2025-02-10D139,58400Derivative, Class A CommonForm 4 ↗
Thomas TuChief Medical Officer2025-02-10A8,420654,348CommonForm 4 ↗
Thomas TuChief Medical Officer2025-02-10A139,584063,776CommonForm 4 ↗
Andrew HykesDirector2025-02-10D16,71900Derivative, Class A CommonForm 4 ↗
Andrew HykesDirector2025-02-10D161,10000Derivative, Class A CommonForm 4 ↗
Andrew HykesDirector2025-02-10A16,7196107,914CommonForm 4 ↗
Andrew HykesDirector2025-02-10A161,100069,015CommonForm 4 ↗
Andrew HykesDirector2025-02-10D16,71900Derivative, Class A CommonForm 4 ↗
Andrew HykesDirector2025-02-10A16,71907,639CommonForm 4 ↗
Catherine SzymanDirector2025-02-19D22,429——CommonForm 4 ↗
Cynthia LuccheseDirector2025-02-19D38,429——CommonForm 4 ↗
Donald MilderDirector2025-02-19D259,126——CommonForm 4 ↗
Dana G. Mead JrDirector2025-02-19D11,148——CommonForm 4 ↗
Andrew HykesDirector2025-02-19D717,637——CommonForm 4 ↗
Thomas TuChief Medical Officer2025-02-19A7,406——CommonForm 4 ↗
Rebecca ChambersDirector2025-02-19D9,684——CommonForm 4 ↗
Andrew HykesDirector2025-02-19D44,693——Derivative, Class A CommonForm 4 ↗
Andrew HykesDirector2025-02-19A20,393——CommonForm 4 ↗
Andrew HykesDirector2025-02-19D1,000——CommonForm 4 ↗
Andrew HykesDirector2025-02-19D1,550——CommonForm 4 ↗
Cynthia LuccheseDirector2025-02-19D49,719——Derivative, Class A CommonForm 4 ↗
Andrew HykesDirector2025-02-19D1,550——CommonForm 4 ↗
Kevin T. StrangeChief Financial Officer2025-02-19D5,293——Derivative, Class A CommonForm 4 ↗
Kevin T. StrangeChief Financial Officer2025-02-19D11,761——Derivative, Class A CommonForm 4 ↗
Kevin T. StrangeChief Financial Officer2025-02-19D67,502——CommonForm 4 ↗
Thomas TuChief Medical Officer2025-02-19D16,231——Derivative, Class A CommonForm 4 ↗
Catherine SzymanDirector2025-02-19D49,719——Derivative, Class A CommonForm 4 ↗
Jonathan D. RootDirector2025-02-19D335——CommonForm 4 ↗
Thomas TuChief Medical Officer2025-02-19D16,599——Derivative, Class A CommonForm 4 ↗
Jonathan D. RootDirector2025-02-19D541,149——CommonForm 4 ↗
Donald MilderDirector2025-02-19D2,831,714——CommonForm 4 ↗
Robert WarnerDirector2025-02-19D12,149——CommonForm 4 ↗
Thomas TuChief Medical Officer2025-02-19D478,767——CommonForm 4 ↗
Karen SilvaPrincipal Accounting Officer2025-02-19D14,719——CommonForm 4 ↗
Andrew HykesDirector2025-02-19D36,085——Derivative, Class A CommonForm 4 ↗
William HoffmanDirector2025-02-19D238,987——CommonForm 4 ↗
Andrew HykesDirector2025-02-19D1,550——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (104 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Andrew Hykes. DEF 14A, filed 2024-03-13. Section “Summary Compensation Table”. As printed: 5,083,365. View filing ↗
  • Section 01, Thomas Tu. DEF 14A, filed 2024-03-13. Section “Summary Compensation Table”. As printed: 2,495,947. View filing ↗
  • Section 01, Mitchell Hill. DEF 14A, filed 2024-03-13. Section “Summary Compensation Table”. As printed: 2,494,947. View filing ↗
  • Section 03, Mitchell Hill RSU. DEF 14A, filed 2024-03-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Thomas Tu RSU. DEF 14A, filed 2024-03-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Thomas Tu OPTION. DEF 14A, filed 2024-03-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Andrew Hykes OPTION. DEF 14A, filed 2024-03-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Andrew Hykes RSU. DEF 14A, filed 2024-03-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Mitchell Hill OPTION. DEF 14A, filed 2024-03-13. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 08, Donald Milder. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 266,428. View filing ↗
  • Section 08, Cynthia Lucchese. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 235,928. View filing ↗
  • Section 08, Jonathan Root, M.D. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 230,928. View filing ↗
  • Section 08, Kirk Nielsen. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 227,062. View filing ↗
  • Section 08, Rebecca Chambers. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 220,928. View filing ↗
  • Section 08, Robert Warner. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 220,928. View filing ↗
  • Section 08, Catherine Szyman. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 220,472. View filing ↗
  • Section 08, Dana G. Mead Jr. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 218,428. View filing ↗
  • Section 08, William Hoffman. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 198,428. View filing ↗
  • Section 08, Andrew Hykes. DEF 14A, filed 2024-03-13. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 02, Thomas Tu 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, William Hoffman 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, William Hoffman 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Tu 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Tu 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin T. Strange 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Tu 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin T. Strange 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin T. Strange 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin T. Strange 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin T. Strange 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin T. Strange 2025-01-01. Form 4, filed 2025-01-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, William Hoffman 2025-01-06. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, William Hoffman 2025-01-06. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Tu 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin T. Strange 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Karen Silva 2025-02-04. Form 4, filed 2025-02-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Tu 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Tu 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Tu 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Tu 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-10. Form 4, filed 2025-02-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Catherine Szyman 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Cynthia Lucchese 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Donald Milder 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Dana G. Mead Jr 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Tu 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Rebecca Chambers 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Cynthia Lucchese 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin T. Strange 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin T. Strange 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kevin T. Strange 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Tu 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Catherine Szyman 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jonathan D. Root 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Tu 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jonathan D. Root 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Donald Milder 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Robert Warner 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Thomas Tu 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Karen Silva 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, William Hoffman 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew Hykes 2025-02-19. Form 4, filed 2025-02-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-04-25. Item 5.07 · say-on-pay result. As reported: 95.35% (votes for as printed: 44,404,487). View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-05-19. Item 5.07 · say-on-pay result. As reported: 92.56% (votes for as printed: 42,519,009). View filing ↗
  • Section 06, 2022 vote. Form 8-K, filed 2022-05-27. Item 5.07 · say-on-pay result. As reported: 87.22% (votes for as printed: 36,070,016). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
  • Section 09b board cost (computed). Computed. Cash 591,178 + equity 1,448,592 + all other 0 = 2,039,770, summed across the director compensation table rows.
  • Silk Road Medical, Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Silk Road Medical's own proxy. As printed: 13,423,834. View filing ↗
  • NovoCure, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in NovoCure's own proxy. As printed: 13,198,354. View filing ↗
  • Abiomed, Section 10b CEO total. DEF 14A, filed 2022-06-28. CEO total compensation as printed in Abiomed's own proxy. As printed: 12,665,992. View filing ↗
  • Glaukos, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Glaukos's own proxy. As printed: 12,034,087. View filing ↗
  • Nevro, Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro's own proxy. As printed: 11,453,548. View filing ↗
  • iRhythm Technologies, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in iRhythm Technologies's own proxy. As printed: 11,003,163. View filing ↗
  • AtriCure, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure's own proxy. As printed: 9,217,620. View filing ↗
  • ShockWave Medical, Section 10b CEO total. DEF 14A, filed 2023-04-21. CEO total compensation as printed in ShockWave Medical's own proxy. As printed: 8,418,871. View filing ↗
  • LivaNova, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in LivaNova's own proxy. As printed: 8,047,217. View filing ↗
  • Inspire Medical Systems, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Inspire Medical Systems's own proxy. As printed: 7,711,784. View filing ↗
  • Staar Surgical Company, Section 10b CEO total. DEF 14A, filed 2026-05-04. CEO total compensation as printed in Staar Surgical Company's own proxy. As printed: 7,522,385. View filing ↗
  • Artivion, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Artivion's own proxy. As printed: 6,883,108. View filing ↗
  • Tandem Diabetes Care, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Tandem Diabetes Care's own proxy. As printed: 6,858,503. View filing ↗
  • AngioDynamics, Section 10b CEO total. DEF 14A, filed 2026-10-08. CEO total compensation as printed in AngioDynamics's own proxy. As printed: 6,060,145. View filing ↗
  • Inari Medical, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2024-03-13. CEO total compensation as printed in Inari Medical, Inc.'s own proxy. As printed: 5,083,365. View filing ↗
  • Penumbra, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Penumbra's own proxy. As printed: 851,621. View filing ↗
  • Section 10a, AngioDynamics reciprocity. DEF 14A. AngioDynamics names Inari Medical, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, ShockWave Medical reciprocity. DEF 14A. ShockWave Medical names Inari Medical, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, STAAR Surgical Company reciprocity. DEF 14A. STAAR Surgical Company names Inari Medical, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗